Reemergence of invasive Haemophilus influenzae type b disease in Alaska: Is it because of vaccination with polyribosylribitol phosphate outer membrane protein complex (PRP-OMPC) or failure to vaccinate with PRP-OMPC?
Dargan
J M
JM
Coplan
P M
PM
Kaplan
K M
KM
Nikas
A
A
D000413:Alaska / Q000453:epidemiology; D001425:Bacterial Outer Membrane Proteins / Q000009:adverse effects / Q000276:immunology; D002353:Carrier State / Q000382:microbiology; D002675:Child, Preschool; D006192:Haemophilus Infections / Q000453:epidemiology* / Q000382:microbiology; D018073:Haemophilus Vaccines / Q000009:adverse effects / Q000276:immunology; D019741:Haemophilus influenzae type b / Q000502:physiology; D006801:Humans; D007198:Indians, North American; D007223:Infant; D007231:Infant, Newborn; D010614:Pharynx / Q000382:microbiology; D011135:Polysaccharides, Bacterial / Q000009:adverse effects / Q000276:immunology; D012424:Rural Population; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000009:adverse effects / Q000276:immunology
D001425:Bacterial Outer Membrane Proteins; D018073:Haemophilus Vaccines; C061964:Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate